Anteris Technologies Global’s (AVR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Anteris Technologies Global (NASDAQ:AVR) in a report released on Friday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company began coverage on Anteris Technologies Global in a research note on Wednesday, March 11th. They issued an “overweight” rating and a $16.00 target price for the company. Lake Street Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Anteris Technologies Global in a research report on Friday, January 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Anteris Technologies Global in a report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.33.

Anteris Technologies Global Stock Performance

AVR opened at $5.19 on Friday. The firm’s fifty day moving average is $5.96 and its two-hundred day moving average is $5.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.73 and a current ratio of 0.73. The firm has a market cap of $504.62 million, a PE ratio of -2.03 and a beta of 1.14. Anteris Technologies Global has a twelve month low of $2.34 and a twelve month high of $6.95.

Anteris Technologies Global (NASDAQ:AVR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.75) earnings per share (EPS) for the quarter. Anteris Technologies Global had a negative net margin of 4,921.27% and a negative return on equity of 536.04%. The firm had revenue of $0.31 million during the quarter. Equities research analysts anticipate that Anteris Technologies Global will post -2.66 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder L1 Capital Pty Ltd bought 5,000,000 shares of Anteris Technologies Global stock in a transaction that occurred on Thursday, January 22nd. The stock was purchased at an average cost of $5.75 per share, with a total value of $28,750,000.00. Following the purchase, the insider owned 13,219,814 shares in the company, valued at approximately $76,013,930.50. This trade represents a 60.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

A number of institutional investors have recently modified their holdings of AVR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Anteris Technologies Global in the first quarter valued at about $32,000. Geode Capital Management LLC grew its holdings in shares of Anteris Technologies Global by 154.3% during the second quarter. Geode Capital Management LLC now owns 420,427 shares of the company’s stock worth $1,593,000 after buying an additional 255,088 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Anteris Technologies Global during the second quarter worth about $49,000. JPMorgan Chase & Co. raised its position in Anteris Technologies Global by 9,958.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,068,328 shares of the company’s stock valued at $4,049,000 after buying an additional 1,057,707 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its stake in Anteris Technologies Global by 9.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 425,000 shares of the company’s stock valued at $1,611,000 after acquiring an additional 35,000 shares in the last quarter.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.